Recall

Bayshore Pharmaceuticals announced Wednesday that it was voluntarily recalling two lots of the medication metformin, which is widely used by diabetics to control blood sugar levels.
Metformin works by reducing the amount of sugar in an individual’s blood by heightening the body’s insulin sensitivity. Over 120 million people around the world have been prescribed metformin for type 2 diabetes. According to the Federal Food and Drug Administration (FDA), some of the metformin distributed by Bayshore Pharmaceuticals has excessive levels of NDMA, which may cause cancer in humans.
Metformin distributed by Bayside Pharmaceuticals was manufactured in 2019 by Beximco Pharmaceuticals Limited, a company located in Bangladesh.
Bayside is recalling the following lots of metformin: Metformin Hydrochloride Extended-Release Tablets USP in the 500-milligram strength in the 1,000 bottle pack size. Look for an NDC number of 76385-128-10 and a lot number of 18641. The medication lists an expiration date of May 2021.
Also recalled are Metformin Hydrochloride Extended-Release Tablets USP in the 750-milligram strength in the 100 bottle pack size. This lot has an NDC number of 76385-129-01 and an identifying lot number of 18657. Bottles from this lot of metformin carry an expiration date of May 2021.
Bayshore Pharmaceuticals is currently notifying customers affected by the recall via phone and recall notification. Until the company can arrange for a return of the product, the metformin should be quarantined and not ingested by patients.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s